Friday, May 10 2024
02:30 PM – 02:45 PM ET - Ballroom 3
258: Validating EPI-321 Safety for FSHD: A Comprehensive Off Target Characterization Platform for Epigenetic Gene Therapies
Linsin Smith - Ph.D.
Epic Bio
Disclosures: L.A. Smith: 1; Commercial Interest i.e. Company X; Epic Bio. 1; What was received? i.e. Honorarium; Salary and Equity. 1; For what role? i.e. Speaker; Employment.
Related Abstract